BioArctic AB (BIOA_B) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to Biotic's presentation for the fourth quarter and for the full year of 2025. It has been a fantastic year for Biotic. In 2025 we entered into a new era that we call the growth era. And we can conclude that we have a transformative year behind us with record financial results. We are making our science accessible to more and more patients than ever before. And I think it's great and reassuring to see that more and more patients are getting access to Lecambi. We are accelerating our innovations. Our portfolio is progressing really well and has been further expanded. And our brain transporter technology is further evolving with new innovations. We have increased focus on business development. We are broadening our collaborations and utilizing our brain transporter technology. And we'll talk more about all this in today's presentation. Next slide, please. Biotic is listed at Nasdaq Stockholm large cap, and this is our disclaimer. Next slide, please. I'm Gunilla Åsvall, and I'm the CEO of Biotic. And I will share today's presentation with our CFO, Anders Martin Lööf, and our chief R&D officer, Johanna Felting, and our chief commercial officer, Anna-Kaja Grönblad. Next slide, please. I'll start our presentation by giving some key highlights. Next slide, please. I'm proud to state that Biotic is among the world leading innovators in precision neurology. We have two key platforms, where the first one is innovation and generation and development of highly selective antibodies that are targeting aggregated, misfolded forms of toxic proteins like leucanumab. And we also have projects targeting alphasnuclein, TDP43 and Huntingtin. The second area is the brain transporter platform, where we have an innovative way to deliver antibodies. And I want to hig...